Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients

Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients

Immunotherapy in the form of ICIs has revolutionized advanced NSCLC treatment algorithms, with ICI-containing combination treatments being the latest addition to approved regimens. However, PD-L1 still represents the only routinely assessed and validated biomarker apart from genetic drivers testing,...

Full description

Bibliographic Details
Main Authors: Luigi Della Gravara, Ciro Battiloro, Antonietta Letizia, Rosa Cantile, Vito D'Agnano, Giacomo Sica, Danilo Rocco
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Journal of Molecular Pathology
Subjects:
advanced NSCLC
immunotherapy
predictive biomarkers
PD-L1
TMB
TILS
Online Access:https://www.mdpi.com/2673-5261/2/2/17

Internet

https://www.mdpi.com/2673-5261/2/2/17

Similar Items